Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.67 |
| ▸ | ROS1 | P08922 | 6/20 | 0.67 |
| ▸ | INSR | P06213 | 3/20 | 0.49 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791425 | 1.00 | ALK (0.67) | ALKROS1INSRIGF1REGFR | |
| SCHEMBL24620263 | 0.93 | ALK (0.59) | ALKROS1INSRIGF1REGFR | |
| SCHEMBL29791434 | 0.93 | ALK (0.59) | ALKROS1INSRIGF1REGFR | |
| SCHEMBL29791545 | 0.88 | ALK (0.52) | ALKROS1EGFRPTK2 | |
| SCHEMBL24620270 | 0.88 | ALK (0.52) | ALKROS1EGFRPTK2 | |
| SCHEMBL24620284 | 0.86 | ALK (0.67) | ALKROS1INSRIGF1REGFR | |
| SCHEMBL29791364 | 0.86 | ALK (0.67) | ALKROS1INSRIGF1REGFR | |
| SCHEMBL24620250 | 0.82 | CCNK (0.66) | ALKEGFRAXLMAP3K7CCNK | |
| SCHEMBL29791347 | 0.82 | CCNK (0.66) | ALKEGFRAXLMAP3K7CCNK | |
| SCHEMBL24620378 | 0.82 | CCNK (0.48) | ALKROS1INSRIGF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | ALK 430/4885ROS1 533/4885INSR 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.